New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
14:37 EDTVRTXVertex makes 'procedural' change to cystic fibrosis studies, TheStreet reports
Vertex Pharmaceuticals swapped the primary and secondary endpoints of two phase III trials investigating its combination cystic fibrosis therapy, making the primary endpoint of both studies the absolute change in lung function, though the company said it considers the move as "more procedural" than anything else and that it "was not based on anything going on in the study or anything observed in the study," reported TheStreet's Adam Feuerstein. Reference Link
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
06:14 EDTVRTXPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use